Table 2:
Procedure related data.
| Variable | Value | |||
| No. PIPACs | 106 | |||
| PIPAC C/D | 79 | |||
| PIPAC OX | 27 | |||
| PIPACs/pt, median (range) | 3 (1–6) | |||
| Median procedure time, minutes (range) | ||||
| PIPAC 1 (n=41) | 96 (34–150) | |||
| PIPAC 2 (n=29) | 85 (52–118) | |||
| PIPAC 3 (n=20) | 82 (22–109) | |||
| Length of stay, all patients | ||||
| 0 days | >0 days | |||
| PIPAC 1 | 10 (24%) | 31 (76%) | ||
| PIPAC 2 | 13 (45%) | 16 (55%) | ||
| PIPAC 3 | 13 (65%) | 7 (35%) | p=0.008 | |
| Length of stay, PIPAC OX | ||||
| 0 days | >0 days | |||
| PIPAC 1 | 1 (11%) | 8 (89%) | ||
| PIPAC 2 | 1 (13%) | 7 (87%) | ||
| PIPAC 3 | 1 (20%) | 4 (80%) | ||
| Length of stay, PIPAC C/D | ||||
| 0 days | >0 days | |||
| PIPAC 1 | 9 (28%) | 23 (72%) | ||
| PIPAC 2 | 12 (57%) | 9 (43%) | ||
| PIPAC 3 | 12 (80%) | 3 (20%) | p=0.002 | |
| Morphine administration after PIPAC | ||||
| PIPAC C/D | PIPAC OX | |||
| PIPAC 1 | 10 (31%) | 6 (66%) | ||
| PIPAC 2 | 5 (23%) | 4 (50%) | ||
| PIPAC 3 | 1 (6%) | 1 (17%) | ||
Unless otherwise stated, the number of patients in each group is shown. C/D, cisplatin/doxorubicin; OX, oxaliplatin; PIPAC, Pressurized Intraperitoneal Aerosol Chemotherapy; pt, patient.